Efficacy and Safety of the Herbal Medicine Sominex ® (Passiflora Incarnata L., Valeriana Officinalis L. and Crataegus Oxyacantha L.), Manufactured by the Laboratory EMS S / A in Patients With Psychophysiological Insomnia

NCT ID: NCT01100645

Last Updated: 2010-10-28

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE3
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-10-31
• Study Completion Date: 2011-02-28

Brief Summary

The main objective of this study is to evaluate the clinical efficacy of the drug Sominex (Valeriana officinalis L., 40 mg, 30 mg Crataegus oxyacantha L. and Passiflora incarnata L. 50 mg) manufactured by the Laboratory EMS S / A, compared to placebo in improving sleep efficiency, based on the response of the sleep quality questionnaire (MSQ) and polysomnographic parameters described below:

• Latency to onset of sleep;
• Total time of sleep;
• Rapid eye movement (REM) sleep latency;
• Duration of REM sleep

Detailed Description

Verify the effectiveness of the drug Sominex compared to placebo based on the improvement of the following parameters measured by the following validated scales:

• Anxiety;
• Daytime sleepiness; Will also be assessed secondary to drug safety testing for the occurrence, type, frequency and intensity of adverse events during treatment.

Conditions

Insomnia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Test

Sominex ® (Passiflora incarnata L. 50 mg, Valeriana officinalis L. 40 mg and Crataegus oxyacantha L. 30 mg)

Group Type: EXPERIMENTAL

Sominex

Intervention Type: DRUG

Passiflora incarnata L.50 mg Valeriana officinalis L.40 mg Crataegus oxyacantha L.30 mg

Placebo

Excipient

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Excipient

Interventions

Sominex

Passiflora incarnata L.50 mg Valeriana officinalis L.40 mg Crataegus oxyacantha L.30 mg

Intervention Type: DRUG

Placebo

Excipient

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Patients who agree and sign the informed consent form (ICF);

2. Adult patients, aged ≥ 18 years and ≤ 65 years, male or female;

3. Patients who agree to perform all study procedures;

4. Patients diagnosed with psychophysiological insomnia;

5. Patients who present in the application of sleep questionnaire result ≥ 25 and ≤ 30 points;

6. Patients presenting in polysomnography change in any of the polysomnographic parameters than the normal range.

Exclusion Criteria

1. Having participated in any experimental study or have ingested any drug trial within 12 months prior to the start of the study;

2. Be in use or have used other medications that interfere with the regular response of the drug at least 04 weeks prior to the start of the study, as benzodiazeínicos, antidepressants with sedative, sedatives, antihistamines and other herbal medicines;

3. Being in treating or have been treated with alternative methods that interfere with the drug response to at least 04 weeks prior to the start of the study, such as behavioral therapies and relaxation techniques, such as yoga, massage, etc.;

4. Be patient with sensitivity to an association of herbal medicines;

5. Present history of alcohol abuse, drugs or medicines;

6. Pregnant or nursing women;

7. Owning a history of liver disease or renal impairment and / or thyroid dysfunction;

8. Patients with a history of restless sleep: nocturnal myoclonus or restless legs syndrome;

9. Patients with a history of snoring or bruxism exaggerated;

10. Diseases that affect sleep, causing pain or immobilization of the patient in bed;

11. Patients who have extensive work or working in night shifts totally or partially nocturnal;

12. Patients in whom polysomnography demonstrating non-characteristic changes in sleep disturbances of psychophysiological origin as narcolepsy, hipopinéia syndrome, upper airway hypersensitivity syndrome of periodic limb movements, sleepwalking, among others;

13. Physical or psychological disorders that might interfere with the analysis of data such as neurosis, depression, muscle atrophy, and / or staying the medical criteria.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Azidus Brasil

INDUSTRY

Sponsor Role: lead

Responsible Party

LAL Clínica Pesquisa e Desenvolvimento Ltda.

Locations

LAL Clinica Pesquisa e Desenvolvimento Ltda

Valinhos, São Paulo, Brazil

Countries

Brazil

Facility Contacts

Alexandre Frederico

Role: primary

Other Identifiers

Version 2

Identifier Type: -

Identifier Source: secondary_id

VCPEMS0210

Identifier Type: -

Identifier Source: org_study_id